Azzad Asset Management Inc /Adv Astrazeneca PLC Transaction History

Azzad Asset Management Inc /Adv

$386 Billion
Q4 2024

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 27, 2025	BUY	$63.2 - $79.58 $3.93 Million - $4.95 Million	62,232 New	62,232 $4.08 Billion
Q3 2024 Oct 07, 2024	SELL	$76.67 - $87.62 $53,822 - $61,509	-702 Reduced 1.14%	61,093 $4.76 Billion
Q2 2024 Jul 30, 2024	SELL	$66.81 - $80.83 $30,465 - $36,858	-456 Reduced 0.73%	61,795 $4.82 Billion
Q1 2024 Apr 19, 2024	BUY	$61.03 - $69.57 $119,862 - $136,635	1,964 Added 3.26%	62,251 $4.22 Billion
Q4 2023 Apr 01, 2024	BUY	$61.89 - $69.28 $33,791 - $37,826	546 Added 0.91%	60,287 $4.06 Billion
Q3 2023 Apr 01, 2024	BUY	$64.85 - $71.7 $48,832 - $53,990	753 Added 1.28%	59,741 $4.05 Billion
Q2 2023 Apr 01, 2024	SELL	$69.91 - $75.81 $726,225 - $787,514	-10,388 Reduced 14.97%	58,988 $4.22 Billion
Q1 2023 Apr 01, 2024	BUY	$63.15 - $71.6 $46,036 - $52,196	729 Added 1.06%	69,376 $4.82 Billion
Q4 2022 Apr 01, 2024	SELL	$54.21 - $70.44 $1.22 Million - $1.59 Million	-22,511 Reduced 24.69%	68,647 $4.65 Billion
Q3 2022 Apr 01, 2024	BUY	$53.02 - $135.75 $90,770 - $232,404	1,712 Added 1.91%	91,158 $4.97 Billion
Q2 2022 Apr 01, 2024	BUY	$59.26 - $71.14 $1.53 Million - $1.83 Million	25,748 Added 40.42%	89,446 $5.71 Billion
Q1 2022 Apr 01, 2024	BUY	$55.72 - $67.12 $448,378 - $540,114	8,047 Added 14.46%	63,698 $4.23 Billion
Q4 2021 Apr 01, 2024	BUY	$54.02 - $63.83 $1.64 Million - $1.94 Million	30,384 Added 120.25%	55,651 $3.24 Billion
Q3 2021 Apr 01, 2024	BUY	$55.56 - $60.79 $88,007 - $96,291	1,584 Added 6.69%	25,267 $1.52 Billion
Q2 2021 Apr 01, 2024	BUY	$48.42 - $60.18 $20,481 - $25,456	423 Added 1.82%	23,683 $1.42 Billion
Q1 2021 Apr 01, 2024	BUY	$47.16 - $54.44 $341,344 - $394,036	7,238 Added 45.18%	23,260 $1.16 Billion
Q4 2020 Apr 01, 2024	BUY	$48.52 - $58.02 $22,513 - $26,921	464 Added 2.98%	16,022 $801 Million
Q3 2020 Apr 01, 2024	BUY	$53.07 - $61.1 $37,149 - $42,770	700 Added 4.71%	15,558 $853 Million
Q2 2020 Apr 01, 2024	SELL	$43.1 - $55.31 $4,353 - $5,586	-101 Reduced 0.68%	14,858 $786 Million
Q1 2020 Apr 01, 2024	SELL	$37.79 - $51.33 $543,457 - $738,176	-14,381 Reduced 49.01%	14,959 $668 Million
Q4 2019 Apr 01, 2024	BUY	$42.46 - $50.46 $3,354 - $3,986	79 Added 0.27%	29,340 $1.51 Billion
Q3 2019 Apr 01, 2024	BUY	$40.12 - $45.47 $219,657 - $248,948	5,475 Added 23.02%	29,261 $1.43 Billion
Q2 2019 Apr 01, 2024	SELL	$37.28 - $41.68 $969 - $1,083	-26 Reduced 0.11%	23,786 $982 Million
Q1 2019 Apr 01, 2024	BUY	$35.49 - $43.02 $8,446 - $10,238	238 Added 1.01%	23,812 $963 Million
Q4 2018 Apr 01, 2024	SELL	$36.86 - $41.49 $22,890 - $25,765	-621 Reduced 2.57%	23,574 $895 Million
Q3 2018 Apr 01, 2024	BUY	$34.76 - $39.72 $10,497 - $11,995	302 Added 1.26%	24,195 $957 Million
Q2 2018 Apr 01, 2024	BUY	$34.55 - $37.05 $825,503 - $885,235	23,893 New	23,893 $839 Million
Q1 2018 Apr 03, 2024	BUY	$32.97 - $36.63 $77,413 - $86,007	2,348 Added 11.16%	23,380 $818 Million
Q4 2017 Apr 03, 2024	BUY	$32.09 - $34.78 $39,181 - $42,466	1,221 Added 6.16%	21,032 $730 Million
Q3 2017 Apr 03, 2024	SELL	$28.96 - $34.0 $1.17 Million - $1.38 Million	-40,476 Reduced 67.14%	19,811 $671 Million
Q4 2012 Apr 08, 2024	SELL	N/A	-15,040 Closed	0 $0
Q3 2012 Apr 08, 2024	SELL	N/A	-45,247	15,040 $720 Million

Others Institutions Holding AZN

# of Institutions

1,367

Shares Held

475M

Call Options Held

6.08M

Put Options Held

4.44M

Price T Rowe Associates Inc Baltimore, MD

60.4M
Shares

$4.44 Billion
0.46% of portfolio
Primecap Management CO Pasadena, CA

41M
Shares

$3.01 Billion
2.12% of portfolio
Capital International Investors Los Angeles, CA

37.5M
Shares

$2.76 Billion
0.48% of portfolio
Bank Of America Corp Charlotte, NC

24M
Shares

$1.77 Billion
0.13% of portfolio
Franklin Resources Inc San Mateo, CA

19.5M
Shares

$1.43 Billion
0.37% of portfolio

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $228B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

News

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.

Account